1
|
Tsuji K, Spears GW, Nakamura K, Tojo T, Seki N, Sugiyama A, Matsuo M. Synthesis and antinephritic activities of quinoline-3-carboxamides and related compounds. Bioorg Med Chem Lett 2002; 12:85-8. [PMID: 11738579 DOI: 10.1016/s0960-894x(01)00671-0] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A series of linomide-related quinoline-3-carboxamides and their analogues was prepared and evaluated for antinephritic activities. The 6-MeS derivative 7a was highly effective in two nephritis models, namely chronic graft-versus-host disease and autoimmune MRL/l mice.
Collapse
Affiliation(s)
- Kiyoshi Tsuji
- Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 1-6, Kashima 2-chome,Yodogawa-ku, 532-8514, Osaka, Japan.
| | | | | | | | | | | | | |
Collapse
|
2
|
Giles FJ, Kantarjian H, O'Brien S, Rios MB, Cortes J, Beran M, Koller C, Keating M, Talpaz M. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leuk Lymphoma 2001; 41:309-19. [PMID: 11378543 DOI: 10.3109/10428190109057985] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The objective of the study was to investigate the toxicity and efficacy of cyclic combination therapy offered to patients with Ph-positive CML having a sub-optimal response to IFN-alpha. Patients in early chronic phase CML were treated with IFN-alpha at 5MU/m(2) daily. Patients who did not achieve cytogenetic response after 6 months of IFN-alpha therapy, or Ph-suppression to less than 35% Ph-positive cells (partial cytogenetic response) after 12 months of therapy were offered cyclic intensive chemotherapy every 6 months, with IFN-alpha maintenance between cycles. The initial 3 cycles included daunorubicin, vincristine, cytosine arabinoside (ara-C) and prednisone (DOAP). Later cycles were given with cyclophosphamide replacing daunorubicin (COAP). Of 74 patients treated, 61 (82%) achieved complete hematologic response (CHR): 51 (69%) had a cytogenetic response, which was major (Ph < 35%) in 31 (42%), and complete in 23 (31%). Fifty-five patients (74%) achieved CHR by 6 months of therapy, 38 (69%; 51% of total) with a cytogenetic response - 13 (24%) had a major cytogenetic response. Seventeen patients received at least 1 course of DOAP therapy. Median survival of the overall cohort of patients was 120 months. With a median follow-up of 145 months (103+ to 155+ months), 40 patients (54%) have died. The median duration of cytogenetic response was 35 months (range 3 to 149+ months) and the estimated 10-year cytogenetic response rate was 37%. A durable complete cytogenetic response was observed in 16 patients (20%) with a median duration of 139+ months (range 12+ to 149+ months), 11 of them (15%) are now off IFN-alpha therapy for a median of 57+ months (range 12+ to 128+ months). The projected 10-year survival was 50% for the study group versus 35% for 208 patients who received other IFN-alpha based regimens at the MD Anderson Cancer Center (p<.01). In conclusion, the addition of intensive chemotherapy may improve survival in patients with CML who have not obtained an adequate cytogenetic response on an IFN-alpha-based regimen.
Collapse
MESH Headings
- Actuarial Analysis
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/toxicity
- Cohort Studies
- Cyclophosphamide/administration & dosage
- Cyclophosphamide/toxicity
- Cytarabine/administration & dosage
- Cytarabine/toxicity
- Cytogenetic Analysis
- Daunorubicin/administration & dosage
- Daunorubicin/toxicity
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Interferon-alpha/administration & dosage
- Interferon-alpha/toxicity
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myeloid, Chronic-Phase/complications
- Leukemia, Myeloid, Chronic-Phase/drug therapy
- Leukemia, Myeloid, Chronic-Phase/mortality
- Male
- Middle Aged
- Prednisolone/administration & dosage
- Prednisolone/toxicity
- Prednisone/administration & dosage
- Prednisone/toxicity
- Risk Factors
- Survival Rate
- Therapeutic Equivalency
- Treatment Outcome
- Vincristine/administration & dosage
- Vincristine/toxicity
Collapse
Affiliation(s)
- F J Giles
- Department of Leukemia; University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Expansion of Philadelphia Chromosome–Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice. Blood 1998. [DOI: 10.1182/blood.v92.9.3318.421k39_3318_3327] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We have developed culture conditions for the efficient expansion of cytotoxic effector cells from peripheral blood mononuclear cells (PBMNCs) by the timed addition of interferon-γ (IFN-γ), interleukin-2 (IL-2), and the monoclonal antibody (MoAb) OKT3. These cells, termed cytokine-induced killer (CIK) cells, are composed primarily of T cells, and the population of cells with the greatest cytotoxic activity is an otherwise rare population of CD3+CD56+ cells that expand dramatically under these culture conditions. CIK cells were expanded from PBMNCs from 13 patients with chronic myeloid leukemia (CML). These cultures contained a variable number of T cells at the start of the culture (median 44%, range 1% to 64%), yet after 21 to 28 days of culture, virtually all of the cells were CD3+ T cells (median 97%, range 90% to 99%). The CD3+CD56+subset of cells expanded significantly (median 25-fold, range 2.2- to 525-fold). CIK cells from all patients showed cytotoxicity against the tumor cell lines OCI-LY8 and K562. In four patients the expanded CIK cells suppressed colony growth of autologous CML blast cells and myeloid progenitor cells. Allogeneic CIK cells from normal donors also suppressed CML colony growth but did not inhibit growth of normal hematopoietic colonies. Twelve of the 13 cultures were exclusively composed of Philadelphia (Ph)-negative cells and one culture had 1 out of 20 Ph-positive metaphases after 4 weeks in culture. Intracellular cytokine production was assayed by fluorescence-activated cell sorter (FACS), and the expanded T-cell cultures produced IL-2, IFN-γ, and tumor necrosis factor- (TNF-), but not IL-4. Both the CD4+ and CD8+ subsets secreted this cytokine profile. To test the in vivo activity of the expanded CIK cells, CML was engrafted into severe combined immunodeficiency disease (SCID) mice using matrigel. After 4 weeks, 4 × 107autologous CIK cells were injected intravenously by tail vein injection into groups of mice, and the animals were sacrificed after a total of 18 weeks. Bcr-abl was detected in the bone marrow or spleen of 5 out of 6 control mice and only 2 out of 13 mice who received the autologous CIK cells (P = .02). In an additional series of animals, the mice did not engraft with CML but instead developed large human Epstein-Barr virus–associated lymphomas by 12 weeks. The mice who received autologous CIK cells at 4 weeks had either no tumor (5) or small tumors (5), whereas all 10 mice that received CIK cells at week 8 developed lymphomas; however, these were not as large as in the 10 control mice who did not receive CIK cells (P = .03). This study shows that CIK cells, which are Ph chromosome–negative, can be expanded from patients with CML and have potent in vitro and in vivo efficacy against autologous tumor cells.
© 1998 by The American Society of Hematology.
Collapse
|
4
|
Expansion of Philadelphia Chromosome–Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice. Blood 1998. [DOI: 10.1182/blood.v92.9.3318] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
We have developed culture conditions for the efficient expansion of cytotoxic effector cells from peripheral blood mononuclear cells (PBMNCs) by the timed addition of interferon-γ (IFN-γ), interleukin-2 (IL-2), and the monoclonal antibody (MoAb) OKT3. These cells, termed cytokine-induced killer (CIK) cells, are composed primarily of T cells, and the population of cells with the greatest cytotoxic activity is an otherwise rare population of CD3+CD56+ cells that expand dramatically under these culture conditions. CIK cells were expanded from PBMNCs from 13 patients with chronic myeloid leukemia (CML). These cultures contained a variable number of T cells at the start of the culture (median 44%, range 1% to 64%), yet after 21 to 28 days of culture, virtually all of the cells were CD3+ T cells (median 97%, range 90% to 99%). The CD3+CD56+subset of cells expanded significantly (median 25-fold, range 2.2- to 525-fold). CIK cells from all patients showed cytotoxicity against the tumor cell lines OCI-LY8 and K562. In four patients the expanded CIK cells suppressed colony growth of autologous CML blast cells and myeloid progenitor cells. Allogeneic CIK cells from normal donors also suppressed CML colony growth but did not inhibit growth of normal hematopoietic colonies. Twelve of the 13 cultures were exclusively composed of Philadelphia (Ph)-negative cells and one culture had 1 out of 20 Ph-positive metaphases after 4 weeks in culture. Intracellular cytokine production was assayed by fluorescence-activated cell sorter (FACS), and the expanded T-cell cultures produced IL-2, IFN-γ, and tumor necrosis factor- (TNF-), but not IL-4. Both the CD4+ and CD8+ subsets secreted this cytokine profile. To test the in vivo activity of the expanded CIK cells, CML was engrafted into severe combined immunodeficiency disease (SCID) mice using matrigel. After 4 weeks, 4 × 107autologous CIK cells were injected intravenously by tail vein injection into groups of mice, and the animals were sacrificed after a total of 18 weeks. Bcr-abl was detected in the bone marrow or spleen of 5 out of 6 control mice and only 2 out of 13 mice who received the autologous CIK cells (P = .02). In an additional series of animals, the mice did not engraft with CML but instead developed large human Epstein-Barr virus–associated lymphomas by 12 weeks. The mice who received autologous CIK cells at 4 weeks had either no tumor (5) or small tumors (5), whereas all 10 mice that received CIK cells at week 8 developed lymphomas; however, these were not as large as in the 10 control mice who did not receive CIK cells (P = .03). This study shows that CIK cells, which are Ph chromosome–negative, can be expanded from patients with CML and have potent in vitro and in vivo efficacy against autologous tumor cells.
© 1998 by The American Society of Hematology.
Collapse
|
5
|
Simonsson B. Treatment of chronic myelogenous leukaemia. Cancer Immunol Immunother 1998; 15:27-31. [PMID: 9643527 DOI: 10.1007/bf02787341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- B Simonsson
- Department of Medicine, University Hospital, Uppsala, Sweden
| |
Collapse
|
6
|
Bhatia R, Forman SJ. Autologous transplantation for the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am 1998; 12:151-72. [PMID: 9523230 DOI: 10.1016/s0889-8588(05)70501-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
There is evidence that benign, Ph-negative hematopoietic progenitors persist in the marrow and blood of some patients with chronic myelogenous leukemia (CML). A number of pilot studies using purged and unpurged marrow or peripheral blood autografts have demonstrated that autologous transplantation can result in transient cytogenetic responses in CML. Although not curative, this procedure may be associated with longer-than-expected patient survival and represents an alternative treatment for patients ineligible for allogeneic transplantation and not responding to interferon-alpha therapy. Several novel approaches are being developed to improve graft purging and eliminate residual leukemia post-transplantation. Such approaches may allow for long-term restoration of Ph-negative hematopoiesis following the procedure.
Collapse
Affiliation(s)
- R Bhatia
- Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, California, USA
| | | |
Collapse
|
7
|
Bhatia R, McGlave PB. Autologous stem cell transplantation for the treatment of chronic myelogenous leukemia. Cancer Treat Res 1997; 77:357-74. [PMID: 9071511 DOI: 10.1007/978-1-4615-6349-5_16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- R Bhatia
- Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
| | | |
Collapse
|
8
|
Abstract
Graft-versus-leukemia (GVL) effect is an immunologically important phenomenon which decreases the relapse rate of leukemia after allogeneic bone marrow transplantation. GVL effect is sometimes associated with the occurrence of graft-versus-host disease (GVHD). Analyses of GVL effect and GVHD showed that these two phenomena were separable in some conditions. Although we cannot yet completely control the development of the GVL effect without inducing GVHD in humans, basic analyses using animal models show potential benefits of the GVL effect for clinical applications. Autologous GVHD is another important phenomenon which can help to eradicate minimal residual disease. Interleukin 2 and/or cyclosporin A are extensively used in animal models and in humans to induce autologous GVHD, showing beneficial effects. In the future, cytokine usage and allogeneic stem cell transplantation or leukocyte infusion appear to be promising in the control of minimal residual disease. Further studies on the mechanisms of GVL effects and GVHD may well open a new era for cell transplantation.
Collapse
Affiliation(s)
- M Imamura
- Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan
| | | | | |
Collapse
|
9
|
Abstract
Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder with an initially chronic course lasting for 3-5 years. It eventually transforms into accelerated and blastic phases, which are generally fatal. CML was one of the first diseases in which a specific chromosomal abnormality was identified, a t(9;22)(q34;q11) or Philadelphia chromosome. CML had been traditionally treated with conventional chemotherapy with hydroxyurea or busulfan. Although these agents can achieve hematologic remissions in most patients, no evidence of sustained disappearance of the chromosomal abnormality was evident. Interferon alpha (IFN-alpha) has been able to achieve hematologic and cytogenic remissions in a significant number of patients, and recent studies show a survival advantage for patients treated with IFN-alpha compared with those treated with conventional chemotherapy. The results of these studies are discussed, and the reasons for discordance among different investigators analyzed in this review. Allogeneic bone marrow transplantation (BMT) may be curative in some patients with CML. The benefits and limitations of this approach in the treatment of CML are also discussed and the results of different alternatives compared. Other alternatives of therapy, including newer chemotherapeutic agents, combinations of IFN-alpha with other agents, and autologous BMT, are presented. The availability of very sensitive techniques for detection of the Philadelphia chromosome at the molecular level has allowed the detection of minimal residual disease. The information available on these measurements is also analyzed. Finally, we discuss the alternatives for patients with accelerated and blastic phase CML, as well as the clinical characteristics and prognosis for patients with Philadelphia-chromosome-negative CML.
Collapse
MESH Headings
- Adult
- Antimetabolites, Antineoplastic/therapeutic use
- Antineoplastic Agents, Alkylating/administration & dosage
- Antineoplastic Agents, Alkylating/therapeutic use
- Antineoplastic Agents, Phytogenic/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Bone Marrow Transplantation
- Busulfan/administration & dosage
- Busulfan/therapeutic use
- Cytarabine/therapeutic use
- Drug Therapy, Combination
- Harringtonines/therapeutic use
- Homoharringtonine
- Humans
- Hydroxyurea/administration & dosage
- Hydroxyurea/therapeutic use
- Immunosuppressive Agents/administration & dosage
- Immunosuppressive Agents/therapeutic use
- Interferon-alpha/therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Middle Aged
- Prognosis
- Time Factors
Collapse
Affiliation(s)
- J E Cortes
- Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
| | | | | |
Collapse
|
10
|
Vaz F, Silva MR, Ascensao JL. Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex. Br J Cancer 1995; 72:1498-503. [PMID: 8519666 PMCID: PMC2034089 DOI: 10.1038/bjc.1995.536] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Roquinimex (Roq) is an immunomodulator known to stimulate cellular immune responses. It is currently used for immunotherapy after bone marrow transplantation (BMT). One of the major features of this compound is an enhancement of natural killer (NK) cell activity and numbers. We studied the in vitro effect of Roq on human peripheral blood NK and adherent lymphokine-activated killer cell (ALAK) activities. In cultures supplemented with recombinant interleukin 2 (rIL-2) (1000 U ml-1) and Roq a significant increase in NK and LAK function was observed without a parallel increase in cell numbers. We also examined the generation of NK cells from human bone marrow (BM) immature progenitors, obtained by purging with 4-hydroperoxycyclophosphamide (4HC). NK cell numbers and activity were both increased when cultures with rIL-2 (10 U ml-1) were supplemented with Roq. These results confirm findings obtained in vivo and in vitro in the murine system and suggest that Roq is an active agent on these lymphoid populations. These properties and good tolerability make Roq an attractive tool for immunotherapy.
Collapse
MESH Headings
- Adjuvants, Immunologic/pharmacology
- Bone Marrow/drug effects
- Bone Marrow Cells
- Bone Marrow Purging
- Cell Count/drug effects
- Cell Division/drug effects
- Cell Division/physiology
- Cells, Cultured
- Cyclophosphamide/analogs & derivatives
- Hematopoietic Stem Cells/cytology
- Hematopoietic Stem Cells/drug effects
- Humans
- Hydroxyquinolines/pharmacology
- Killer Cells, Lymphokine-Activated/drug effects
- Killer Cells, Lymphokine-Activated/physiology
- Killer Cells, Natural/drug effects
- Killer Cells, Natural/physiology
- Leukemia, Erythroblastic, Acute
- Leukocytes, Mononuclear/drug effects
- Lymphocyte Activation/drug effects
- Phenotype
- Stimulation, Chemical
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- F Vaz
- Portuguese Institute of Oncology, Lisbon, Portugal
| | | | | |
Collapse
|
11
|
Kouides PA, Rowe JM. A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis. Leuk Res 1995; 19:763-70. [PMID: 7500655 DOI: 10.1016/0145-2126(95)00070-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Fourteen consecutive patients with chronic myelogenous leukemia (CML) blast crisis were treated with a more dose-intensive regimen of daunorubicin (70 mg/m2 per day on days 1-3) and cytosine arabinoside (200 mg/m2 per day as continuous infusion on days 1-9) than usually used in de novo acute myelogenous leukemia. The median age of the patients was 50 years (27-78 years). Eleven of 13 evaluable patients were aplastic at day 14 after a single course of therapy (11/13, 85%). Over-all response rate (complete + partial response) was 9/13 (69%). Restoration to chronic phase was achieved in 7/13 patients (54%) lasting a median of 78 days (49-235 days). However, four of these seven patients proceeded to bone marrow transplant (BMT) and so the true remission duration for this therapy cannot be determined. Treatment-related mortality was 4/14 (29%). Presently, four of nine patients evaluable are surviving post-induction, three S/P allogeneic BMT (0.6, 3.8, 5 years) and one patient S/P autologous BMT (3.3 years post-induction). These results of an intensive induction regimen achieving marrow aplasia in all except one patient to date warrants further study as the first step possibly towards BMT after CML blast crisis.
Collapse
Affiliation(s)
- P A Kouides
- Rochester General Hospital, University of Rochester School of Medicine, New York 14621, USA
| | | |
Collapse
|